An announcement from Zevra Therapeutics ( (ZVRA)) is now available. Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

Zevra Therapeutics ( (ZVRA)) has provided an announcement. Zevra Therapeutics is undergoing significant organizational changes to sharpen its focus on late-stage clinical and commercial ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock ...

Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the business earned ($0.40) earnings per share.

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...

Zevra Therapeutics (ZVRA – Research Report) received a Buy rating and a price target from Cantor Fitzgerald analyst Kristen Kluska today. The company’s shares closed yesterday at $8.24.

CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment ...

In a remarkable display of resilience, Zomedica Corp. (ZVRA) stock has soared to a 52-week high, reaching a price level of $8.45. This peak comes amidst a broader market rally that ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...